Advantage Therapeutics, Inc
Publicly observedMiami, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Miami | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Advantage Therapeutics, Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | EBP3RA2ERYZ2 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies
USD 1,249,368.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies
USD 1,249,957.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.